中文  English

杨向阳

发布时间:2013-03-29 10:41:07  浏览次数:1362619  来源:博鳌亚洲论坛

杨向阳

著名天使投资人,源政投资创始人,中国生物医药投资第一人。杨向阳先生现任深圳市源政投资发展有限公司董事长和深圳市源兴生物医药科技有限公司总裁,是一位拥有逾20年经验的企业家及天使投资人。杨先生1987年从清华大学毕业后进入深圳大学任教,后自己创办企业,先后参与创办及投资了十多家生物医药、健康医疗及信息技术等领域的高科技企业,包括与清华控股有限公司联合创办的拥有多项自主研发基因治疗及细胞治疗技术平台的源兴生物,拥有世界第一个肿瘤基因治疗新药的赛百诺,全球产销规模最大的肝素钠原料药生产商海普瑞,干细胞临床治疗研究世界领先的北科生物,中国领先的第三代网络游戏企业麒麟游戏等。杨先生是深圳市第四、五届政协委员,清华企业家协会主席,深圳市创新总裁俱乐部常务副会长,华汇通投资投资委员会中方主席,以及SAIF Partners的投资合伙人。杨先生毕业于清华大学应用数学系,获理学学士和硕士学位。

Renowned angel investor, founder of the Yuanzheng Investment and the no.1 biomedicine investor in China. Mr. Yang Xiangyang currently serves as Chairman of Shenzhen Yuanzheng Investment and Development Co., Ltd. and Chairman and President of Yuanxing Bio-Pharm Science & Technology Co., Ltd. He is an entrepreneur and angel investor with more than 20 years of experience. Mr. Yang graduated from Tsinghua University in 1987 and upon graduation, enrolled at Shenzhen University. Later, he set up his own own business. He has successfully co-founded and invested in more than a dozen high-tech enterprises in the fields of biomedicine, healthcare and information technology. These include Yuanxing Bio-Pharm, a company with several gene therapy and cell therapy technology platforms jointly established with Tsinghua Holdings Co., Ltd.; SiBiono which has developed the world's first gene therapy drug for tumor diseases; Hepalink, the world’s largest heparin sodium API manufacturer; Beike Biotechnology, a world leader in stem cell clinical treatment research; and Kirin Games, a leading third-generation online game enterprise in China. Mr. Yang is a member of the Fourth and Fifth Shenzhen Committee of the CPPCC, President of the Tsinghua Entrepreneur Association, Executive Vice-President of the Shenzhen Club of Innovative Presidents, the Chinese President of the SBI & TH Venture Capital Investment Committee and Internet Partner of SAIF Partners. Mr. Yang graduated from the Department of Applied Mathematics of Tsinghua University and received a Bachelor of Science and a master's degree.